<DOC>
	<DOCNO>NCT00571870</DOCNO>
	<brief_summary>Gonadotropin-releasing hormone ( GnRH ) antagonists widely use prevention premature luteinizing hormone ( LH ) surge control ovarian hyperstimulation ( COH ) vitro fertilization embryo transfer ( IVF-ET ) since late 1990 's . Many year pass since GnRH antagonist introduce prevent premature LH surge stimulate cycle . However , still consensus optimal GnRH antagonist protocol . Attempts modify GnRH antagonist protocol make improve COH outcome . However , meta-analysis 27 randomize control trial , include recent report , show significantly low clinical ongoing pregnancy rate antagonist group . Thus , additional effort need identify optimal stimulation protocol achieve good follicular embryonic development improve pregnancy rate COH use GnRH antagonist . Given assumption detrimental effect GnRH antagonist pregnancy rate , current protocol , hypothesize short duration GnRH antagonist administration might improve outcome .</brief_summary>
	<brief_title>Gonadotropin-releasing Hormone Antagonist Triggering Day : A Randomized Controlled Study</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Hormone Antagonists</mesh_term>
	<mesh_term>Cetrorelix</mesh_term>
	<criteria>Both ovary present morphological abnormality Normal ovulatory cycle cycle lengths 25 35 day Basal serum FSH ( day 3 ) level &lt; 15 mIU/mL Body mass index ( BMI ) range 18 27 kg/m2 History poor ovarian response Evidence endocrine abnormality , , hyperprolactinemia , thyroid dysfunction , polycystic ovary syndrome Hydrosalpinx Severe endometriosis ( stage IIIIV )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>